<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>BACKGROUND</h3>
<p>Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermoepidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients.</p>
</sec>
<sec><h3>AIM</h3>
<p>This study aims to assess the effect of topical formulation based on <italic>Arnebia euchroma</italic> (AE) on lesions induced by EB.</p>
</sec>
<sec><h3>MATERIALS AND METHODS</h3>
<p>All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16.</p>
</sec>
<sec><h3>RESULTS</h3>
<p>Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively).</p>
</sec>
<sec><h3>CONCLUSION</h3>
<p>Hochobeh ointment may be effective in treating EB skin and mucosal lesions.</p>
</sec>
</abstract>

BACKGROUND
Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermoepidermal junction and painful blisters on the skin and mucous membranes. Currently, there is almost no definite treatment for EB patients.

AIM
This study aims to assess the effect of topical formulation based on Arnebia euchroma (AE) on lesions induced by EB.

MATERIALS AND METHODS
All patients with EB diseases treated with Hochobeh ointment (AE+Beewax+Olive oil) in 2022 at our dermatological clinic were included in the study. EB diseases were diagnosed based on the following criteria: (1) clinical features (2) histopathological findings (3) Linear depositions of IgG, IgA, IgM 4. salt-split skin (SSS) or other immune serological tests compatible with the diagnosis of EB disease. Hochobeh ointment and lotion treatment were initiated. Clinical evaluations were repeated 3 and 7 days after the treatment began, and photographs were taken to document the changes in clinical severity. EB Disease Activity and Scarring Index (EBDASI) and EB Quality of Life (EB-QoL) questionnaires were used to assess the severity of EB and the quality of life, respectively. All statistical analyses were performed using statistical package for the social sciences version 16.

RESULTS
Overall, fourteen patients were included. Improvement in clinical features, including reduction of infection and inflammation and improvement of wound healing, was observed. EBDASI and EB-QoL scores decreased significantly after treatment (91.5 ± 45.7 vs. 68.9 ± 43, p = 0.001; 24.6 ± 6.7 vs. 18 ± 5.2, p = 0.001, respectively).

CONCLUSION
Hochobeh ointment may be effective in treating EB skin and mucosal lesions.

Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

Mazandaran University of Medical Sciences

Department of Infectious Disease, Antimicrobial Resistance Research Center, Faculty of Medicine

South East European Journal of Immunology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

BACKGROUND
Epidermolysis bullosa (EB) is a skin fragility disorder that results in the disruption of the dermoepidermal junction and painful blisters on the...

Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

Online veröffentlicht: 03. Jan. 2024

Seitenbereich: 56 - 61

Eingereicht: 28. Apr. 2023

Akzeptiert: 03. Juli 2023

DOI: https://doi.org/10.3889/seejim.2023.6035

Schlüsselwörter
Arnebia, Epidermolysis bullosa, Quality of life, Dermatology

© 2023 Amirsaleh Abdollahi et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Topical Formulation Based on Arnebia euchroma as a Novel Possible Efficient Treatment on Epidermolysis Bullosa Lesions: A Case Series of Fourteen Patients

Online veröffentlicht: 03. Jan. 2024

Seitenbereich: 56 - 61

Eingereicht: 28. Apr. 2023

Akzeptiert: 03. Juli 2023

DOI: https://doi.org/10.3889/seejim.2023.6035

SchlüsselwörterArnebia, Epidermolysis bullosa, Quality of life, Dermatology

© 2023 Amirsaleh Abdollahi et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Schlüsselwörter
Arnebia, Epidermolysis bullosa, Quality of life, Dermatology